Effects of body mass index (BMI) and smoking on the pharmacokinetics of fentanyl

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28290

Enrollment

Registered

2014-07-07

Start date

2014-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All patients using a stable dose of a fentanyl (Durogesic ®) patch (for at least 8 days).

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: • age > 18 years; • stable use and dose of fentanyl patch (Durogesic ®) for at least 8 days, irrespective of the dose used; • written informed consent.

Exclusion criteria

Exclusion criteria: • Using fentanyl as rescue medication (other opioids are allowed) • Serious psychiatric illness, confusion of intellectual disability • The use of strong cytochrome P450 inhibitors or inducers.

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints. Pharmacokinetics (clearance, AUC etc)	—

Contacts

Public ContactW.H. Oldenmenger

Erasmus Medical Center, Daniel den Hoed Cancer Center, P.O. Box 5201

w.h.oldenmenger@erasmusmc.nl+31 (0)10 4391439

Outcome results